BridgeBio Pharma (BBIO) Cash & Equivalents (2018 - 2026)

BridgeBio Pharma has reported Cash & Equivalents for 9 years, with the latest figure at $879.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 62.76% year-over-year to $879.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $879.9 million (up 62.76% YoY) and the FY2025 annual result came in at $570.1 million, up 58.46% from the prior year.
• Cash & Equivalents improved to $879.9 million in Q1 2026 per BBIO's latest filing, from $570.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $879.9 million in Q1 2026 and troughed at $266.3 million in Q3 2024.
• A 5-year average of $460.3 million and a median of $408.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 167.95% in 2022, then plunged 47.28% in 2024.
• Over 5 years, Cash & Equivalents stood at $376.7 million in 2022, then fell by 0.2% to $375.9 million in 2023, then declined by 4.3% to $359.8 million in 2024, then soared by 58.46% to $570.1 million in 2025, then soared by 54.33% to $879.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $879.9 million, $570.1 million, and $283.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.